ライフサイエンスコーパス: neoantigen

1 cell lymphoma that expresses OVA as a model neoantigen.

2 n anti-tumor vaccinal effect against a model neoantigen.

3 ess was also observed upon immunization with neoantigen.

4 tiated if the transgene product represents a neoantigen.

5 use prostatic acid phosphatase as the target neoantigen.

6 mon HLA subtype, thereby creating a "public" neoantigen.

7 that may impair CD8(+) T cell recognition of neoantigens.

8 tide complexes, resulting in the creation of neoantigens.

9 s and immunotherapeutic approaches targeting neoantigens.

10 a was enhanced in tumors enriched for clonal neoantigens.

11 as a biomarker to detect T cells that target neoantigens.

12 rt therapeutic developments targeting clonal neoantigens.

13 as compared with non-synonymous SNV derived neoantigens.

14 ng the immune response toward tumor-specific neoantigens.

15 mit the rapid identification of mutant tumor neoantigens.

16 se mutations as a source of patient-specific neoantigens.

17 enesis, it is clear that tumors express many neoantigens.

18 response driven by one or more tumor-derived neoantigens.

19 , CCS, and DSRCT can serve as tumor-specific neoantigens.

20 can bind class I HLA molecules and serve as neoantigens.

21 g is an effective platform to uncover tumour neoantigens.

22 hemotherapy by leveraging responses to tumor neoantigens.

23 t targets up to 20 predicted personal tumour neoantigens.

24 ency of somatic mutations and tumor-specific neoantigens.

25 fusions in prostate cancers that may produce neoantigens.

26 identifying which gene fusions may generate neoantigens.

27 diatric cancers, likely due their paucity of neoantigens.

28 Regarding neoantigens, 47% of the lung ADC and 53% of the lung SqC

29 h the presence of T cells directed at cancer neoantigens, a class of HLA-bound peptides that arise fr

30 Predicted neoantigens activated T cells from the patients treated

31 1 pathway impairs CD4(+) T cell responses to neoantigen and induces a state of immune senescence in i

32 To investigate the roles of tumor-specific neoantigens and alterations in the tumor microenvironmen

33 Immune responses to citrullinated neoantigens and clinical efficacy of costimulation block

34 T cells specific for immunoglobulin-derived neoantigens and found these cells could mediate killing

35 which can trigger an increased abundance of neoantigens and greater mutant-binding specificity.

36 iminished responsiveness to vaccination with neoantigens and infection with de novo pathogens in the

37 clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epito

38 lyse the immunogenicity of tumour-associated neoantigens and the aetiology of autoimmune disease.

39 view focuses on a discussion of mutant tumor neoantigens and their use in personalizing cancer immuno

40 ntial to simultaneously identify immunogenic neoantigens and tumor-reactive T cell clonotypes.

41 Identification of these neoantigens and understanding how they form might prove

42 and with a trend for lower overall mutation, neoantigen, and CNV loads in TNBC and HER2(+) cancers.

43 etailed analyses of mutation load, predicted neoantigens, and immune cellular infiltration in tumors

44 ation of naturally processed ligands, cancer neoantigens, and T cell epitopes.

45 Thus, when a neoantigen appears in established tumors, the immune sys

46 tigens per individual tumor, suggesting that neoantigens are frequent in most tumors.

47 However, it is also possible that while neoantigens are present, an effective immune response ca

48 ce suggesting that T cells that target tumor neoantigens arising from cancer mutations are the main m

49 ons and reduced expression of genes encoding neoantigens as potential mediators of resistance to immu

50 to human lymphoma implicates immunoglobulin neoantigens as targets for lymphoma immunotherapy.

51 r, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking.

52 l PDAC samples harbor potentially targetable neoantigens; (b) T cells are present but generally show

53 humoral immune responses to T cell-dependent neoantigens, bacteriophage phiX174 and keyhole limpet he

54 icting response to ICB and for the design of neoantigen-based therapeutic vaccines.

55 accumulate and establishment of responses to neoantigens becomes compromised because of the reduced g

56 efore investigated the response to a contact neoantigen before liver transplantation as a predictor o

57 lterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies fro

58 we demonstrate a relationship between clonal neoantigen burden and overall survival in primary lung a

59 with the molecular smoking signature, higher neoantigen burden, and DNA repair pathway mutations; eac

60 LCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregula

61 Through integrated analysis of ITH and neoantigen burden, we demonstrate a relationship between

62 n associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern wi

63 onalized immunotherapy with patient-specific neoantigens, but a general methodology for stimulating s

64 The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirm

65 that deregulated phosphorylation can create neoantigens by promoting binding to major histocompatibi

66 notion by showing that clonal expression of neoantigens by tumor cells, rather than overall mutation

67 rker C3d and the terminal complement complex neoantigen C5b-9 along the outer surface of the Schwann

68 We hypothesized that vaccination with neoantigens can both expand pre-existing neoantigen-spec

69 l humoral response to a CD4 T cell-dependent neoantigen challenge soon after BMT.

70 Cytotoxic chemotherapy-induced subclonal neoantigens, contributing to an increased mutational loa

71 ognosis had significantly lower mutation and neoantigen counts than did lymphocyte-poor TNBCs with po

72 sgene-encoded Vkappa8 L chain, most likely a neoantigen created by the insertion of the transgene int

73 cell responses appear to be directed toward neoantigens created by somatic mutations; however, direc

74 Furthermore, neoantigens derived from indel mutations were nine times

75 ch for the prediction and validation of such neoantigens derived from individual tumors and presented

76 ymphocytes that target tumor-specific mutant neoantigens--derived from products encoded by mutated ge

77 monstrate the application of our gene fusion neoantigen discovery pipeline, called INTEGRATE-Neo, by

78 btype are compatible with an autogenic tumor neoantigen-driven humoral immune response.

79 ponse against MSI colorectal cancer-specific neoantigens, establishing a preclinical rationale to tar

80 ey also prime naive T-cell responses against neoantigens ex vivo.

81 To discern whether targetable neoantigens exist in PDAC, we performed a comprehensive

82 lonal antibody C3-9, which is specific for a neoantigen exposed in activated forms of C3.

83 ed cancer-associated Tn glycoform of MUC1, a neoantigen expressed in a variety of cancers.

84 common oral bacteria are cross-reactive with neoantigens expressed in oxLDL.

85 , STING signaling neither promoted growth of neoantigen-expressing LLC, nor did it induce IDO in TDLN

86 ng that all cases of proven NH contained TCC neoantigen far in excess of cases of other neonatal live

87 Two main factors determine neoantigen fitness: the likelihood of neoantigen present

88 ic HLA typing, we identified candidate tumor neoantigens for each patient.

89 opeptidome and in the discovery of potential neoantigens for immunotherapies.

90 ping post-translational epitope diversity or neoantigen formation in organ tissues.

91 halothane metabolism and trifluoroacetylated neoantigen formation remains unidentified.

92 the halothane metabolite responsible for the neoantigen formation that initiates halothane hepatitis.

93 mplex, the terminal complement cascade (TCC) neoantigen formed in the assembly of MAC.

94 viduals to trifluoroacetylated liver protein neoantigens, formed by oxidative halothane metabolism.

95 However computing capabilities to identify neoantigens from genomic sequencing data are a limiting

96 kflow for identifying patient-specific tumor neoantigens from next generation sequencing data.

97 to discover tumor-specific mutant peptides (neoantigens) from somatic missense mutations, the field

98 cell recognition of CD1a proteins and lipid neoantigen generated in vivo by phospholipases.

99 Somatic mutations and candidate neoantigens generated from these mutations were characte

100 The search for these "neoantigens" has been facilitated by the combination of

101 Antibodies to a neoantigen, HAV, developed when vaccination was delayed

102 vaccine) or respond to a recall antigen and neoantigen (hepatitis A virus [HAV] vaccine) after 3 vac

103 These data suggest that neoantigen heterogeneity may influence immune surveillan

104 ovides scalable computation capabilities for neoantigen identification while eliminating the need to

105 Importantly, low-fitness neoantigens identified by our method may be leveraged fo

106 Alternative biomarkers such as tumor neoantigens identified through whole-exome sequencing an

107 All animals responded to neoantigen immunization, indicating that the modified re

108 the periphery, and improved the response to neoantigen immunization.

109 clones on metastatic progression, suggesting neoantigen immunoediting.

110 uthors' laboratory have shown that feeding a neoantigen in an attempt to induce oral tolerance is not

111 expression of dystrophin, a tissue-specific neoantigen in dystrophic recipients.

112 when beta-galactosidase was eliminated as a neoantigen in mice transgenic for lacZ.

113 The percentage of hepatocytes containing TCC neoantigen in NH was much greater than that in non-NH li

114 Deposition of C9 neoantigen In the vasculature of porcine organs perfused

115 scribed model allows identification of those neoantigens in human cancer that serve as suitable T cel

116 Here we discover neoantigens in human mantle-cell lymphomas by using an i

117 ll reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer,

118 pothesis that the large proportion of mutant neoantigens in mismatch repair-deficient cancers make th

119 n leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma.

120 its fitness as a weighted effect of dominant neoantigens in the subclones of the tumour.

121 om lack of negative selection for peripheral neoantigens in the thymus after BMT and that tolerance a

122 en qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as C

123 Ischemia induces expression of multiple neoantigens, including lipid alterations that are recogn

124 nic polypeptides, and (4) physically loading neoantigen into iDR-NCs.

125 adjuvants, as well as tumor-specific peptide neoantigens into antigen presenting cells (APCs) in lymp

126 We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor i

127 tionally, although the precise nature of the neoantigen is not known, the T cells described in this r

128 erging data suggest that recognition of such neoantigens is a major factor in the activity of clinica

129 rate of primary allergic sensitization to a neoantigen, keyhole limpet hemocyanin, using a unique mo

130 Responses to neoantigen (KLH) and T cell-independent responses to pne

131 of immunotherapy have been modest, except in neoantigen-laden mismatch repair-deficient tumors.

132 We elucidated a neoantigen landscape that is specifically present in tum

133 The predicted median (range) neoantigen load (predicted neoepitopes per sample) was p

134 ad, predicted neoantigen load, and expressed neoantigen load did not demonstrate significant associat

135 These observations indicate that neoantigen load may form a biomarker in cancer immunothe

136 Prediction of neoantigen load was performed using sequencing data from

137 In responding patients, mutation and neoantigen load were reduced from baseline, and analysis

138 e association of mutation load and predicted neoantigen load with therapeutic benefit and (2) determi

139 In ER(+) cancers, mutation load, neoantigen load, and CNV load weakly but positively asso

140 Missense mutation load, predicted neoantigen load, and expressed neoantigen load did not d

141 Overall mutational load, neoantigen load, and expression of cytolytic markers in

142 eterogeneity, somatic total mutational load, neoantigen load, and somatic copy number alteration leve

143 f clonal heterogeneity, total mutation load, neoantigen load, copy number variations (CNV), gene- or

144 lting information can characterize a tumor's neoantigen load, its cadre of infiltrating immune cell t

145 mutated and MSI ECs are associated with high neoantigen loads and number of TILs, which is counterbal

146 Evidence suggests that high mutation and neoantigen loads are associated with response to immune

147 bMMRD GBM harbored mean neoantigen loads seven to 16 times higher than those in

148 expansion of T cell clones in the setting of neoantigen loss.

149 aluation of skin test responses to a contact neoantigen may facilitate tailoring of immunosuppressive

150 reactive microbial epitopes, consistent with neoantigen molecular mimicry.

151 Remarkably, iDR-NC/neoantigen nanovaccines elicit 8-fold more frequent neoa

152 d can be used to elicit primary responses to neoantigens (neoAgs).

153 cribing greater immunogenicity to increasing neoantigen number alone did not.

154 we found that tumours with both the highest neoantigen number and the most abundant CD8(+) T-cell in

155 ein IIb heavy chain, and 5E5, specific for a neoantigen on glycoprotein IIIa expressed on activated p

156 by which certain natural Abs that recognize neoantigens on apoptotic cells, in naive mice and those

157 Pathogenic Abs recognize neoantigens on the ischemic tissue, activate complement,

158 l reactivities were directed against mutated neoantigens or a cancer germline antigen, rather than ca

159 cinations targeting either MHC class I or II neoantigens or tumor-associated antigens rendered up to

160 to many determinants (whether deposited as "neoantigens" or normal constituents of the extracellular

161 However, no recurrent neoantigen peptide sequences predicted responder patient

162 Neoantigen peptides were tested for the ability to activ

163 d estimated dozens to thousands of predicted neoantigens per individual tumor, suggesting that neoant

164 here appeared to be naive T-cell anergy to a neoantigen (phiX174) during active CD11a blockade, witho

165 Characterizing HLA LOH with LOHHLA refines neoantigen prediction and may have implications for our

166 Neoantigen prediction bMMRD GBM was compared with respon

167 Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both t

168 ant peptide identification and NetMHCpan for neoantigen prediction.

169 We assessed in-silico tumour-specific neoantigen predictions by mutation type with pan-cancer

170 ith the human leukocyte antigen complex, and neoantigen presence has recently been shown to correlate

171 Thus, neoantigen presentation by epidermal LCs results in eith

172 ermine neoantigen fitness: the likelihood of neoantigen presentation by the major histocompatibility

173 ered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neo

174 Investigating the specific neoantigen qualities promoting T-cell activation in long

175 More broadly, we identify neoantigen quality as a biomarker for immunogenic tumour

176 A neoantigen quality fitness model conferring greater immu

177 Such differences in neoantigen quality might explain why cancer immunotherap

178 ivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenici

179 tegy to develop personalized therapies using neoantigen-reactive lymphocytes or TCRs to treat cancer.

180 regions, thereby leading to the synthesis of neoantigens recognized by CD8(+) T cells.

181 ersonalized identification and validation of neoantigens remains a major challenge.

182 otherapy on lymphocytes primed against tumor neoantigens remains poorly defined.

183 targeted 3, 3 and 1 unique, patient-specific neoantigens, respectively.

184 Neoantigens resulting from the inherent genomic instabil

185 binds to bacteria, thereby exposing the same neoantigen(s) as with heparin.

186 ed on T-cell responses against virus-encoded neoantigen(s) expressed in tumor cells.

187 Analysis of tumour-specific neoantigens showed that enrichment of indel mutations fo

188 we identify T cells restricted to two known neoantigens simultaneously in tumours, spleens and lymph

189 This assay uses a neoantigen specific capture antibody directed to the ami

190 infiltration with CD103(+)CD8(+) T cells and neoantigen-specific CD8 T lymphocytes against the marker

191 tumor-reactive repertoire, including mutated neoantigen-specific CD8(+) lymphocytes, whereas only a f

192 ramer staining can identify and characterize neoantigen-specific CD8(+) T cells in mice bearing T3 me

193 The analysis of neoantigen-specific CD8(+) T cells in tumour-bearing ind

194 In one responder, neoantigen-specific CD8+ T cell responses paralleled tum

195 and significantly inhibit the progression of neoantigen-specific colorectal tumors.

196 licited up to 47-fold greater frequencies of neoantigen-specific CTLs than soluble vaccines and even

197 ne led to an increase in naturally occurring neoantigen-specific immunity and revealed previously und

198 rsonalized screening approach, we identified neoantigen-specific lymphocytes in the peripheral blood

199 gen nanovaccines elicit 8-fold more frequent neoantigen-specific peripheral CD8(+) T cells than CpG,

200 ient demonstrated rapid in vivo expansion of neoantigen-specific T cell clones that were reactive to

201 , suggesting that anti-PD-1 therapy enhances neoantigen-specific T cell reactivity.

202 Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in

203 s and gene-engineered lymphocytes expressing neoantigen-specific T cell receptors (TCRs) isolated fro

204 tribute to inadequate formation of virus and neoantigen-specific T cell responses during chronic HCV

205 We show that neoantigen-specific T cells and gene-engineered lymphocy

206 results provide insights into the nature of neoantigen-specific T cells and the effects of checkpoin

207 tic mutations; however, direct evidence that neoantigen-specific T cells cause regression of establis

208 We further show that neoantigen-specific T cells display a different phenotyp

209 Thus, in addition to the emergence of neoantigen-specific T cells previously documented upon a

210 ression, with expansion of the repertoire of neoantigen-specific T cells.

211 ith neoantigens can both expand pre-existing neoantigen-specific T-cell populations and induce a broa

212 ytometry and high-dimensional analyses, that neoantigen-specific, tumour-infiltrating T cells are hig

213 ctivates T cells through generation of small neoantigens, such as free fatty acids and lysophospholip

214 Autoantibodies to common autoantigens and neoantigens, such as IgG Fc and citrullinated peptides,

215 ly recognize and respond to tumor-associated neoantigens (TANs) in much the same way as they would to

216 ntrol animals with bacteriophage phiX-174, a neoantigen that requires the interaction of antigen-pres

217 unclear, but might involve the formation of neoantigens that activate adaptive immunity.

218 ines and are presented by dendritic cells as neoantigens that activate T cells and promote hypertensi

219 jury is initiated when natural Abs recognize neoantigens that are revealed on ischemic cells.

220 tigens and constitute a class of immunogenic neoantigens that are unmasked during tumor immune evasio

221 sect the immune response to patient-specific neoantigens that arise as a consequence of tumor-specifi

222 PTEN loss and had reduced expression of two neoantigens that demonstrated strong immunoreactivity wi

223 Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells

224 they acquire mutations, some of which create neoantigens that influence the response of patients to i

225 for tumours based on immune interactions of neoantigens that predicts response to immunotherapy.

226 tion burden (p < 0.001) and presented clonal neoantigens that were associated with increased immune c

227 osylation of beta cell proteins may generate neoantigens; therefore, resistance of ALR islets to nitr

228 Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss m

229 Bacteriophage phiX174 was used as a model neoantigen to assess T-cell-dependent humoral immunity.

230 ng the relative MHC binding affinity of each neoantigen to its wild type and a nonlinear dependence o

231 Since FVIII protein is a neoantigen to these mice, sustaining therapeutic plasma

232 nlinear dependence on sequence similarity of neoantigens to known antigens.

233 motherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkp

234 geted 58 (60%) and 15 (16%) of the 97 unique neoantigens used across patients, respectively.

235 ent studies in Nature examine the effects of neoantigen vaccines on patients with stage III or IV mel

236 l survival in murine tumor models treated by neoantigen vaccines.

237 itative defects in B and T cell responses to neoantigen vaccines.

238 CMI to a neoantigen was difficult to establish.

239 nrichment by cell panning suggested that the neoantigen was not membrane expressed or was expressed a

240 showed that the presence of mutant-specific neoantigens was associated with upregulation of antigen

241 e number of predicted MHC Class I-associated neoantigens was correlated with cytolytic activity and w

242 T cells recognizing clonal neoantigens were detectable in patients with durable cli

243 -infiltrating lymphocytes reactive to clonal neoantigens were identified in early-stage non-small cel

244 Although neoantigens were long-envisioned as optimal targets for

245 tered antibody responses to T cell-dependent neoantigens were observed, but immunologic tolerance to

246 responses, including responses to one mutant neoantigen, were amplified effectively with therapy and

247 hepatocytes showed intense staining for TCC neoantigen, whereas hepatocytes in non-NH liver disease

248 related with activated T-cell recognition of neoantigens, which are tumour-specific, mutated peptides

249 ncer can be translated into peptides, termed neoantigens, which can be recognized by the immune syste

250 s model conferring greater immunogenicity to neoantigens with differential presentation and homology

251 Our results identify neoantigens with unique qualities as T-cell targets in p